Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Vijay Peddareddigari et al.|The Lancet Oncology|2012Cited by 541
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal MelanomaRichard D. Carvajal, Gary K. Schwartz, Jeffrey A. Sosman et al.|JAMA|2014Cited by 429
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Karl D. Lewis et al.|The Lancet Oncology|2018Cited by 216
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Giuseppe Gullo, Karl D. Lewis et al.|Journal of Clinical Oncology|2024Cited by 37
LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)Alexander Stratigos, M.G. Fury, Ketty Peris et al.|Annals of Oncology|2020Cited by 14